BEIJING — The Jackson Laboratory has announced plans to open a dedicated quarantine facility for the importation into China of its trademarked mice for biomedical research.
The National Institute of Biological Sciences in Beijing will provide these quarantine services solely for The Jackson Laboratory. The Laboratory is also authorizing iBio Logistics for order fulfillment and transportation of its mice in mainland China. As part of this role, iBio Logistics will provide Mandarin-speaking customer support, quotation, order placement and delivery on behalf of the Laboratory.
“With these efforts, The Jackson Laboratory is increasing access for academic and drug discovery scientists in China to premium quality research mouse models with the goal of helping the research community generate impactful discoveries using mouse models of the highest quality and health standards in the world,” said Dr. Auro Nair, executive vice president of The Jackson Laboratory and president of JAX Mice, Clinical and Research Services.
“The Jackson Laboratory will achieve this goal through having complete assurance and control of the entire supply chain of JAX Mice, from production in the U.S. to arrival at clients’ sites in China, thereby ensuring quality and timeliness.”
Additionally, the laboratory has opened offices in Shangai, in the Zhangjiang Hi-tech Research Park in Pudong. “The new physical presence and employees based out of Shanghai will allow us to better empower scientific researchers in China,” Nair said. “This will be accomplished through improved access to mouse models and sharing of scientific insights to accelerate biological discovery and drug development.”
As part of its education mission, The Laboratory planned to host a Preclinical Mouse Models Forum on Nov. 12 in Hong Kong, Nov. 14 in Shanghai and Nov. 16 in Beijing. Discussion topics included the selection and use of immunodeficient mice, preclinical research applications using NSG and humanized mice and models and services for drug development.
Dr. Charles Lee, scientific director of The Jackson Laboratory for Genomic Medicine, will be collaborating with Dr. Kai Ye of the Xi’an Jiaotong University (XJTU) and the First Affiliated Hospital of Xi’an Jiaotong University (XJTU1AH).
Lee has been appointed an adjunct professor and is co-leading the establishment of a precision medicine initiative at XJTU1AH in Northwest China, under the supervision of the National Health and Family Planning Commission.
Lee will establish a program with XJTU researchers and XJTU1AH physicians and staff, and will explore opportunities for more expanded collaboration between the institutions.
Using his expertise in genomic structural variation to advance an understanding of the complex genomic structures and variants, and gene networks, and also uncover the genomic basis of diseases. Some of the most advanced genetic and cell engineering technologies will subsequently be used to develop novel therapies for treating human diseases. He will also utilize The Jackson Laboratory’s PDX platform to evaluate cancer therapy options and enhance our understanding of anti-cancer drug resistance in patients.
“I am looking forward to collaborating with Dr. Kai Ye and his team and colleagues at XJTU1AH and XJTUs to develop and implement critical tools for clinicians in Xi’an, China to help them make more accurate diagnoses of genetic tests as well as accelerate the development and translation of precision medicine solutions for treating human diseases,” said Lee.